With a market capitalization (market cap) of $3.66B — a measure of how much the company is worth — Parabilis Medicines, Inc. ranks #1,568 among the 2,444 companies tracked, and 191st in Healthcare as of November 11, 2026. Shares trade at $30.02, down 1.15% on the day.
As of November 11, 2026 · Prices may be delayed
of 2,444 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series and can differ when the share count changes. Returns below show the total change over each period. Use the CAGR calculator to calculate an annualized return. CAGR calculator. Market cap vs. stock price.
Listed less than one year ago
Listed less than one year ago
Listed less than six months ago
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation November 6, 2026. The headline market cap is from the ranking update on November 11, 2026.
| Year | As of | Market cap | Annual change | Share-price close |
|---|---|---|---|---|
| 2026Latest available | Nov 6, 2026 | $824.75M | — | $28.53 |
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Ranking figure $3.66B as of November 11, 2026.
Market cap = share price × shares outstanding.
Parabilis Medicines, Inc.'s ranking market cap is the reported market cap from the latest ranking update, with a share price of $29.97 as of November 11, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $824.75M on November 6, 2026. See how the ranking works.
The ranking snapshot ($3.66B as of November 11, 2026) is FMP company-screener market cap. The historical observation ($824.75M on November 6, 2026) is FMP historical-market-capitalization for the same ticker. The live quote market cap agrees with the ranking snapshot. This page does not replace one series with the other.
Current shares outstanding are unavailable from the latest quote. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 2,023,175 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2025 weighted-average shares would give about $60.63M. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Undefined when revenue is zero
Undefined when revenue is zero
FY 2025
FY 2025
Undefined when revenue is zero
FY 2025
Undefined when revenue is zero
FY 2025
FY 2025
FY 2025
Quote as of . Prices may be delayed. Day figures refer to the quote's trading session.
Latest quote: $29.97. The headline price of $30.02 is from the ranking update on Nov 11, 2026. These updates can differ in timing.
Largest U.S.-listed companies in the same sector. These companies may serve different markets.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #11 | Eli Lilly and Company LLY | $1.35T | +1.44% |
| #19 | Johnson & Johnson JNJ | $675.92B | -0.47% |
| #23 |
Parabilis Medicines, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of November 11, 2026, Parabilis Medicines, Inc. (PBLS) is worth $3.66B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Parabilis Medicines, Inc.’s book equity is about −$16.52M. Market cap is the market value of the outstanding shares. As of November 11, 2026, its market cap is $3.66B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Parabilis Medicines, Inc. ranks #1,568 among the 2,444 companies tracked on MarketCapLens. In Healthcare it ranks #191 of 357.
Financial figures are annual and labeled with their fiscal year (FY). Current-price P/E uses the latest available share price and annual earnings per share.
Listed this year; no prior year-end value to compare
Listed less than five years ago
Undefined when revenue is zero
Return on equity data unavailable for FY 2025
FY 2025
Return on assets data unavailable for FY 2025
FY 2025
| $519.48B |
| +0.20% |
| #30 | Merck & Co., Inc. MRK | $364.98B | -0.48% |
| #31 | UnitedHealth Group Incorporated UNH | $363B | +1.89% |
| #37 | Novartis AG NVS | $308.34B | -0.26% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #1565 | Crescent Energy Company CRGY | $3.68B | +1.46% |
| #1566 | Bread Financial Holdings, Inc. BFH | $3.67B | -1.94% |
| #1567 | Primoris Services Corporation PRIM | $3.67B | -1.91% |
| #1569 | Enphase Energy, Inc. ENPH | $3.66B | -4.95% |
| #1570 | Viking Therapeutics, Inc. VKTX | $3.65B | -1.14% |
| #1571 | Nicolet Bankshares, Inc. NIC | $3.65B | -0.11% |
Parabilis Medicines, Inc.’s ranking market cap of $3.66B comes from the same snapshot as the rest of this site, as of November 11, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 2,023,175. The ranking snapshot ($3.66B as of November 11, 2026) is FMP company-screener market cap. The historical observation ($824.75M on November 6, 2026) is FMP historical-market-capitalization for the same ticker. The live quote market cap agrees with the ranking snapshot. This page does not replace one series with the other.
Parabilis Medicines, Inc. (PBLS) shares trade at $30.02, down 1.15% on the day, as of November 11, 2026.
Live P/E is share price divided by annual earnings per share. Sales-based ratios such as price/sales and operating margin are also blank when revenue is zero — not a 0× multiple.